PRNewswire (Tue, 26-May 8:00 AM ET)
DarioHealth Reports First Quarter 2026 Financial and Operating Results
PRNewswire (Wed, 13-May 6:30 AM ET)
DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
PRNewswire (Mon, 4-May 8:30 AM ET)
PRNewswire (Mon, 20-Apr 8:00 AM ET)
PRNewswire (Mon, 13-Apr 8:00 AM ET)
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
PRNewswire (Thu, 19-Mar 6:30 AM ET)
DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
PRNewswire (Wed, 11-Mar 8:30 AM ET)
PRNewswire (Tue, 10-Mar 8:00 AM ET)
PRNewswire (Tue, 3-Mar 8:00 AM ET)
Market Chameleon (Thu, 25-Sep 3:34 AM ET)
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Dariohealth Corp. trades on the NASDAQ stock market under the symbol DRIO.
As of May 27, 2026, DRIO stock price climbed to $7.70 with 6,851 million shares trading.
DRIO has a market cap of $56.31 million. This is considered a Micro Cap stock.
Last quarter Dariohealth Corp. reported $6 million in Revenue and -$.95 earnings per share. This beat revenue expectation by $105,200 and missed earnings estimates by -$.05.
In the last 3 years, DRIO traded as high as $91.60 and as low as $5.94.
The top ETF exchange traded funds that DRIO belongs to (by Net Assets): VXF, DFSU, DFMC.
DRIO has underperformed the market in the last year with a price return of -46.5% while the SPY ETF gained +30.9%. DRIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.4% and -11.3%, respectively, while the SPY returned +9.1% and +1.7%, respectively.
DRIO support price is $7.01 and resistance is $8.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRIO shares will trade within this expected range on the day.